Founded on Strong Science

In 1988, Leonard S. Schleifer, MD, PhD, left his research career at Cornell University to create Regeneron Pharmaceuticals, Inc., a biotechnology company based on the founding principle that a singular dedication to strong science would lead to important new medicines. With this mission in mind, Dr. Schleifer assembled a nine-member scientific advisory board, including three Nobel laureates - Drs. Alfred G. Gilman, Michael S. Brown and Joseph L. Goldstein, to help guide the young company, with Dr. Schleifer serving as the Company's Chief Executive Officer. Working with its prestigious scientific advisory board, Regeneron initially focused its efforts on discovering treatments for some of the most complex diseases including those related to the brain and central nervous system.

Vagelos Joins as Chairman of the Board

Following the negotiation of collaboration with highly-respected partners, Regeneron completed a successful initial public offering in 1991. In 1995, Dr. Schleifer and the Regeneron Board recruited P. Roy Vagelos, MD, renowned former Chairman and CEO of Merck & Co., Inc., to join Regeneron as Chairman of the Board. Dr. Vagelos considered several opportunities after retiring from Merck, but elected to join Regeneron after recognizing the commercial potential of a company that had steadily developed into one of the foremost research operations in the biotechnology field.

Expanding Into More Diverse Disease Settings

Dr. Vagelos encouraged the Company to expand its core strengths of scientific research and technology development into more diverse disease settings, including cancer, eye diseases, and select inflammatory diseases.

Creating an Innovative Environment to Support Discovery

Led by Chief Scientific Officer, George D. Yancopoulos, MD, PhD, who has been with the Company since 1989, Regeneron has developed a reputation for attracting and retaining some of the most highly-respected scientific researchers in this field. The Company's founding principle that strong science would lead to important new medicines has been instrumental in creating an innovative scientific environment that encourages and supports discovery. These discoveries have led to development of the current product candidate pipeline and technology platforms.

Regeneron has Product Candidates in All Phases of Development

Today, Regeneron currently has three product candidates in late-stage development: aflibercept (VEGF Trap), which is in the third and final stage of clinical trials for the treatment of cancer; VEGF Trap-Eye, also in the third phase of clinical testing to treat eye diseases; and rilonacept (IL-1 Trap), which Regeneron has submitted for approval to the FDA to treat CAPS, a spectrum of rare inflammatory disorders.

New Technology Helps Accelarate Discovery

Looking to the future, Regeneron intends to use its suite of proprietary technologies, called VelociSuite™, to accelerate discovery and development of new antibody product candidates, the first of which will enter clinical testing before the end of 2007.